Skip to main content
. 2020 Mar 5;12:1631–1639. doi: 10.2147/CMAR.S232930

Figure 1.

Figure 1

(A, B) Overall survival (OS) and Disease-free survival (DFS) curves in all TESCC patients. (C, D) OS and DFS curves in TESCC patients with negative lymph nodes; (E, F) OS and DFS curves in TESCC patients with positive lymph nodes.